Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. senior Avg
|
New words:
absorbed, ACE, Actinium, adaptive, adulterated, Agriculture, ahead, aim, aimed, alpha, Amerisource, antiviral, ARC, attend, attendant, AWE, beneficiary, biliary, billed, Bone, bribe, buying, Cardinal, catastrophic, category, CCA, ccRCC, Ceiling, chair, chance, chargeback, cholangiocarcinoma, chosen, closure, COBRA, cold, Colorado, conflict, constitutionality, copay, CRADA, cyberwarfare, Danish, Darmstadt, degradation, dental, destroyed, disaster, dispensing, diversification, downstream, endorsement, England, Enzyvant, epidermal, escape, evidentiary, faster, FD, Florida, fluid, frozen, FSS, God, GU, Hampshire, histology, HMR, Horizon, HPV, hypoxia, ice, ICI, immigration, impeded, ineffective, ineligible, infection, inflation, injunction, instability, interaction, IST, Jebediah, jeopardy, journey, justification, kickback, landmark, Ledell, LinkedIn, macroeconomic, malignancy, McKesson, MHRA, nationwide, navigate, NCCN, NiKang, nondiscrimination, nonrevocation, opt, overcharged, path, payer, percentile, phenomenon, philosophy, Polytechnic, pool, PPACA, PREA, preexisting, pro, proliferation, prompt, proper, PSP, qualification, radioisotope, radiotherapy, rata, reactivate, ready, reassign, Recordati, registry, reinforce, resell, resistant, resupply, Retail, RTF, salvaged, Scotland, screening, seasonal, sector, SI, SIP, solid, solution, specialty, stagnant, standing, stratified, supersede, surface, Surgical, survey, talent, terrorist, tract, trajectory, TriCare, true, Twitter, UF, unanimously, unpaid, upcoming, vaccine, Vermont, video, Warhead, wholesale, wholly, Worcester
Removed:
AbbVie, adherence, AG, al, allegedly, altogether, Anderson, appeal, appealed, Arizona, Array, Assistant, attest, auction, Bauman, Bayer, Bernard, Betta, Binghamton, biomarker, BioPharma, Bob, borrowed, brand, bringing, Brooklyn, calculating, cancellable, capitalizable, captioned, Celgene, center, Century, circumvent, clarify, colorectal, Columbia, complaint, confirmation, cooperate, counsel, crizotinib, crossover, CTA, David, deferment, delivered, DePinho, derived, direction, discordance, dismissal, dispute, division, dosed, Downstate, dropout, Ehrlich, electorate, Eli, escrow, Escudier, ESMO, estimable, evaluable, evidenced, experiencing, exploiting, faculty, favoring, fellowship, flow, Foundation, Fred, fulfill, geographic, glesatinib, graduated, Gustave, Hackel, hazard, hearing, hedge, hematology, Houston, Hutchinson, Hutchison, Iceland, imbalance, Incyte, Institut, investigative, irrespective, Iyer, jeopardize, Johnston, Julie, juncture, Keith, keytruda, leaving, lenalidomide, Levine, ligand, Lilly, liquidation, LLP, load, Matthew, mature, MD, mediated, MediPharma, Megace, memorandum, merestinib, Mirati, MMRF, modified, motion, MOU, moved, MPH, multicenter, Myeloma, Needle, overhaul, Park, pazopanib, pembrolizumab, penalty, Pennsylvania, perpetual, played, pomalyst, pomolidimide, pose, prejudice, prepaid, Professor, prolong, purported, purportedly, qualifying, reclassified, reconsideration, referring, reflecting, regime, regorafenib, removed, Renuka, reposition, resolution, resubmission, retrospective, revalued, revlimid, RMS, Ronald, Roswell, Roussy, rulemaking, Sarcopenia, savolitinib, Seattle, serve, session, settled, Slichenmyer, Southern, speculative, stipulation, Stivarga, sunitinib, SUNY, supplied, Sutent, tasked, Taxpayer, technique, telephone, tepotinib, territorial, tied, trended, trillion, Tuan, unspecified, vacate, variability, viral, voted, Votrient, Washington, William, Windham, withholding, Xalkori, Yervoy, York
Filing tables
Filing exhibits
- 10-K Annual report
- 3.1 EX-3.1
- 10.19 EX-10.19
- 10.20 EX-10.20
- 10.21 EX-10.21
- 10.22 EX-10.22
- 10.23 EX-10.23
- 10.24 EX-10.24
- 10.32 EX-10.32
- 10.39 EX-10.39
- 10.47 EX-10.47
- 10.48 EX-10.48
- 21.1 EX-21.1
- 23.1 EX-23.1
- 31.1 EX-31.1
- 31.2 EX-31.2
- 32.1 EX-32.1
- 32.2 EX-32.2
- Download Excel data file
- View Excel data file
Related press release
Associated AVEO transcripts
AVEO similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
a.Registration Statement (Form S-8 Nos. 333-221838, 333-189565, 333-175390, 333-165530, 333-250276, and 333-256993) of AVEO Pharmaceuticals, Inc., and
a.Registration Statement (Form S-3 No. 333-212051 and No. 333-249982) of AVEO Pharmaceuticals, Inc.;
of our reports dated March 14, 2022, with respect to the consolidated financial statements of AVEO Pharmaceuticals, Inc and the effectiveness of internal control over financial reporting of Aveo Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) for the year ended December 31, 2021.
/s/ Ernst & Young LLP
Boston, Massachusetts
March 14, 2022